Home › Funds › Merck & Co., Inc. › NEUP
Merck & Co., Inc. position in NEUP
NEUPHORIA THERAPEUTICS INC · Health Care
Merck & Co., Inc. reported holding 10,027 shares of NEUP (NEUPHORIA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$36K, representing 0.00% of its reported portfolio and ranking #13 among its reported holdings. Merck & Co., Inc. has disclosed NEUP holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Merck & Co., Inc.'s NEUP position evolved
Merck & Co., Inc. first disclosed a stake in NEUP in Q4 2024 at 10,027 shares (US$34K). The position peaked in Q3 2025 at 10,027 shares, worth US$118K. Across 8 filings, Merck & Co., Inc. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 10,027 shares valued at US$36K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 10.03K | $34.39K | New |
| Q1 2025 | 10.03K | $57.76K | Hold |
| Q2 2025 | 10.03K | $71.19K | Hold |
| Q3 2025 | 10.03K | $118.22K | Hold |
| Q4 2025 | 10.03K | $38.91K | Hold |
| Q1 2026 | 10.03K | $40.81K | Hold |
| Q2 2026 | 10.03K | $43.82K | Hold |
| Q3 2026 | 10.03K | $35.70K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NEUP and 13F data
NEUP (NEUPHORIA THERAPEUTICS INC) is a Health Care company. 20 other funds we track also report a position in NEUP — the largest reported positions include Lynx1 Capital Management LP (US$3.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NEUP
- Lynx1 Capital Management LP 875.33K sh · $3.83M · Q2 2026
More on Merck & Co., Inc.
FAQ
How long has Merck & Co., Inc. held NEUP?
Merck & Co., Inc. has disclosed NEUP holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Merck & Co., Inc.'s current position in NEUP?
As of Q3 2026, Merck & Co., Inc. holds 10.03K shares of NEUP (NEUPHORIA THERAPEUTICS INC), valued at $35.70K, representing 0.00% of its reported portfolio and ranking #13.
Has Merck & Co., Inc. been buying or selling NEUP?
In the latest 13F filing (Q3 2026), Merck & Co., Inc. held unchanged its position in NEUP. The position peaked in Q3 2025 at 10.03K shares.
Which other funds hold NEUP?
Other major institutional holders of NEUP include Lynx1 Capital Management LP, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.